These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 16822091

  • 1. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM.
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [Abstract] [Full Text] [Related]

  • 2. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.
    Leucht S, Heres S.
    J Clin Psychiatry; 2006; 67 Suppl 5():3-8. PubMed ID: 16822090
    [Abstract] [Full Text] [Related]

  • 3. Risks versus benefits of different types of long-acting injectable antipsychotics.
    McEvoy JP.
    J Clin Psychiatry; 2006; 67 Suppl 5():15-8. PubMed ID: 16822092
    [Abstract] [Full Text] [Related]

  • 4. Relapse prevention and recovery in the treatment of schizophrenia.
    Schooler NR.
    J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
    [Abstract] [Full Text] [Related]

  • 5. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
    Kane JM.
    J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
    [Abstract] [Full Text] [Related]

  • 6. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR.
    J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 11. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
    Schanda H, Stompe T.
    Neuropsychiatr; 2010 Dec; 24(1):14-26. PubMed ID: 20146916
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Medication adherence and the use of long-acting antipsychotics in bipolar disorder.
    El-Mallakh RS.
    J Psychiatr Pract; 2007 Mar; 13(2):79-85. PubMed ID: 17414683
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
    Bhanji NH, Chouinard G, Margolese HC.
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dose response of prophylactic antipsychotics.
    Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, Casey DE, Hassan M.
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [Abstract] [Full Text] [Related]

  • 20. Management strategies for the treatment of schizophrenia.
    Kane JM.
    J Clin Psychiatry; 1999 Mar; 60 Suppl 12():13-7. PubMed ID: 10372604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.